Mats Brune Per-Ola Andersson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mats Brune Per-Ola Andersson has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
H. Wadenvik
Hematology Section, Department of Internal Medicine, Sahlgrenska University Hospital, University of Göteborg, S-41345 Göteborg, SwedenTel.: +46-31-3421000 Fax: +46-31-820269
2 shared publicationsB. Ridell
Department of Pathology, Sahlgrenska University Hospital, Göteborg, Sweden
1 shared publicationD. Stockelberg
Hematology Section, Department of Internal Medicine, Sahlgrenska University Hospital, University of Göteborg, S-41345 Göteborg, SwedenTel.: +46-31-3421000 Fax: +46-31-820269
1 shared publication- Hans Wadenvik
Hematology Section, Department of Internal Medicine, Sahlgrenska University Hospital, University of Göteborg, Göteborg, Sweden
1 shared publication J. Kutti
Hematology Section, Department of Internal Medicine, Sahlgrenska University Hospital/Sahlgrenska, S-41345 Gothenburg, SwedenFax: 0046-31-416488
1 shared publicationS Jacobsson
1 shared publication
Latest Publications
- 15 September 2000
- Published by Springer Nature in Annals of Hematology
- Vol. 79 (9) , 507-513
A transforming growth factor-β1-mediated bystander immune suppression could be associated with remission of chronic idiopathic thrombocytopenic purpura
Bystander immune suppression has been demonstrated in experimental models of oral immune tolerance induction. This phenomenon is associated with expression of transforming growth factor (TGF)-β1 and T-helper cell (Th) 2 cytokines. We have studied serum levels of Th cytokines and B- and T-lymphocyte subsets in chronic idiopathic thrombocytopenic purpura (ITP), a disorder in which the production of platelet autoantibodies might be caused by a cytokine network dysregulation. Forty-six patients with ITP were separated into three groups depending on the platelet count (pltc): (1) 150×109/l. We found significantly elevated plasma levels of the Th3 cytokine TGF-β1 in patients with pltc >150×109/l (23.5±2.8 ng/ml), compared with patients with pltc 9/l (2.3±0.6 ng/ml;P9/l (7.2±1.7 ng/ml;PP9/l had significantly lower levels (0.6±0.1 pg/ml) than both patients with pltc 50–150×109/l (1.8±0.1 pg/ml;PP9/l and splenectomised patients had significantly higher levels of CD4+CD25+ activated T cells [26.2±14.8% (PP150×109/l were significantly elevated (26.6±16.0%;P<0.05) compared with controls (17.4±7.6%). In conclusion, our data corroborate previous findings of elevated numbers of activated T cells in chronic ITP patients with active disease, but neither a clear-cut Th1 nor a Th2 serum cytokine profile could be established. However, ITP in remission was associated with elevated TGF-β1, which might be a part of a bystander immune suppression. We propose that the effect of possible expression of TGF-β1 by oral immune tolerance induction deserves to be explored in ITP patients with an active disease.
- 15 September 2000
- Published by Springer Nature in Annals of Hematology
- Vol. 79 (9) , 507-513
A transforming growth factor-β1-mediated bystander immune suppression could be associated with remission of chronic idiopathic thrombocytopenic purpura
Bystander immune suppression has been demonstrated in experimental models of oral immune tolerance induction. This phenomenon is associated with expression of transforming growth factor (TGF)-β1 and T-helper cell (Th) 2 cytokines. We have studied serum levels of Th cytokines and B- and T-lymphocyte subsets in chronic idiopathic thrombocytopenic purpura (ITP), a disorder in which the production of platelet autoantibodies might be caused by a cytokine network dysregulation. Forty-six patients with ITP were separated into three groups depending on the platelet count (pltc): (1) 150×109/l. We found significantly elevated plasma levels of the Th3 cytokine TGF-β1 in patients with pltc >150×109/l (23.5±2.8 ng/ml), compared with patients with pltc 9/l (2.3±0.6 ng/ml;P9/l (7.2±1.7 ng/ml;PP9/l had significantly lower levels (0.6±0.1 pg/ml) than both patients with pltc 50–150×109/l (1.8±0.1 pg/ml;PP9/l and splenectomised patients had significantly higher levels of CD4+CD25+ activated T cells [26.2±14.8% (PP150×109/l were significantly elevated (26.6±16.0%;P<0.05) compared with controls (17.4±7.6%). In conclusion, our data corroborate previous findings of elevated numbers of activated T cells in chronic ITP patients with active disease, but neither a clear-cut Th1 nor a Th2 serum cytokine profile could be established. However, ITP in remission was associated with elevated TGF-β1, which might be a part of a bystander immune suppression. We propose that the effect of possible expression of TGF-β1 by oral immune tolerance induction deserves to be explored in ITP patients with an active disease.
- 18 January 2000
- Published by Springer Nature in Annals of Hematology
- Vol. 79 (1) , 40-42
Leukemic transformation of essential thrombocythemia without previous cytoreductive treatment
Blastic transformation of essential thrombocythemia (ET) preceded by chemotherapy is occasionally described in the literature. In ET as well as in other myeloproliferative disorders the leukemogenic effect of alkylating agents and 32P is well established, and recent reports also indicate a certain leukemogenic effect of hydroxyurea in these disorders. However, leukemic transformation in untreated ET seems to be a rare event. This is probably due to the fact that, at some time during their clinical course, most ET patients receive chemotherapy and are thereby exposed to leukemogenic challenge. We report on a woman with ET who had not received cytoreductive treatment prior to the development of acute myeloid leukemia, indicating that this transformation was a natural progression of her disorder.
- 18 January 2000
- Published by Springer Nature in Annals of Hematology
- Vol. 79 (1) , 40-42
Leukemic transformation of essential thrombocythemia without previous cytoreductive treatment
Blastic transformation of essential thrombocythemia (ET) preceded by chemotherapy is occasionally described in the literature. In ET as well as in other myeloproliferative disorders the leukemogenic effect of alkylating agents and 32P is well established, and recent reports also indicate a certain leukemogenic effect of hydroxyurea in these disorders. However, leukemic transformation in untreated ET seems to be a rare event. This is probably due to the fact that, at some time during their clinical course, most ET patients receive chemotherapy and are thereby exposed to leukemogenic challenge. We report on a woman with ET who had not received cytoreductive treatment prior to the development of acute myeloid leukemia, indicating that this transformation was a natural progression of her disorder.
- 1 January 2000
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 39 (7) , 849-855
Remission Inversion and no Transplant-related Mortality - A Single Centre Experience of Autologous Stem Cell Transplantation in Malignant Lymphoma
Between 1989 and 1998 93 patients with malignant lymphoma were treated, in our centre, with high-dose chemotherapy and autologous stem cell transplantation. Diagnosis according to the REAL-classification were: 38 patients with high-grade lymphoma (diffuse large B-cell lymphoma (DLCL) (n = 26), anaplastic T-cell (n = 5), lymfoblastic (n = 3) and others (n = 4)), 31 patients with low-grade lymphoma (follicular (n = 18), mantle cell (n = 4), B-CLL (n = 3) and others (n = 6)) and, finally, 24 patients with Hodgkin's disease. The source of stem cells was bone marrow (14 patients), peripheral blood stem cells (64 patients) or a combination of both sources (15 patients). There was no early ( < 100 days) transplant-related mortality. One patient died 11 months post-transplant in unexplained liver failure and all other causes of death were related to relapse of lymphoma. So far, no case of myelodysplastic syndromes or secondary acute leukacmia's has occurred. Overall survival (OS) and progression-free survival (PFS) are: (a) DLCL (26 patients, 4-year probability) OS 40%. PFS 33%; (b) follicular (18 patients, 3-year probability) OS 79%, PFS 52%; (c) Hodgkin's lymphoma (24 patients, 5-year probability) OS 65%, PFS 55%. Out of 52 evaluable patients, 34 (65%) have reached remission inversion. The most important findings are no early transplantation-related mortality, remission inversion in a majority of patients, and so far no cases of secondary myelodysplastic syndromes (MDS) acute myelogenous leukaemias (AML). Concerning OS and PFS, our results seem to be in accordance with other centres.
- 1 January 2000
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 39 (7) , 849-855
Remission Inversion and no Transplant-related Mortality - A Single Centre Experience of Autologous Stem Cell Transplantation in Malignant Lymphoma
Between 1989 and 1998 93 patients with malignant lymphoma were treated, in our centre, with high-dose chemotherapy and autologous stem cell transplantation. Diagnosis according to the REAL-classification were: 38 patients with high-grade lymphoma (diffuse large B-cell lymphoma (DLCL) (n = 26), anaplastic T-cell (n = 5), lymfoblastic (n = 3) and others (n = 4)), 31 patients with low-grade lymphoma (follicular (n = 18), mantle cell (n = 4), B-CLL (n = 3) and others (n = 6)) and, finally, 24 patients with Hodgkin's disease. The source of stem cells was bone marrow (14 patients), peripheral blood stem cells (64 patients) or a combination of both sources (15 patients). There was no early ( < 100 days) transplant-related mortality. One patient died 11 months post-transplant in unexplained liver failure and all other causes of death were related to relapse of lymphoma. So far, no case of myelodysplastic syndromes or secondary acute leukacmia's has occurred. Overall survival (OS) and progression-free survival (PFS) are: (a) DLCL (26 patients, 4-year probability) OS 40%. PFS 33%; (b) follicular (18 patients, 3-year probability) OS 79%, PFS 52%; (c) Hodgkin's lymphoma (24 patients, 5-year probability) OS 65%, PFS 55%. Out of 52 evaluable patients, 34 (65%) have reached remission inversion. The most important findings are no early transplantation-related mortality, remission inversion in a majority of patients, and so far no cases of secondary myelodysplastic syndromes (MDS) acute myelogenous leukaemias (AML). Concerning OS and PFS, our results seem to be in accordance with other centres.
- 3 June 1998
- Vol. 95 (23) , 2712-4
[A forgotten fraudulent bean--a case of favism. Fava bean may cause life-threatening hemolysis in predisposed persons].
- 3 June 1998
- Vol. 95 (23) , 2712-4
[A forgotten fraudulent bean--a case of favism. Fava bean may cause life-threatening hemolysis in predisposed persons].